<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000630913">
  <TermName>alvocidib</TermName>
  <TermPronunciation>(al-VOH-sih-dib)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of several types of cancer. It stops cells from dividing and may kill cancer cells. It is a type of cyclin-dependent kinase (CDK) inhibitor. Also called flavopiridol and HMR 1275.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000722548" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;alvocidib&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000722547" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;alvocidib&quot;" language="es" id="_4"/>
  <SpanishTermName>alvocidib</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer. Impide que las células se multipliquen y puede destruir células cancerosas. Es un tipo de inhibidor de la cinasa dependiente de ciclinas (CDK). También se llama flavopiridol y HMR 1275.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-02-12</DateFirstPublished>
  <DateLastModified>2009-02-12</DateLastModified>
</GlossaryTerm>
